<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:media="http://search.yahoo.com/mrss/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>latestage &#8211; USA NEWS LIVE</title>
	<atom:link href="https://bloggingthree.soflytech.com/tag/latestage/feed/" rel="self" type="application/rss+xml" />
	<link>https://bloggingthree.soflytech.com</link>
	<description>All About USA NEWS</description>
	<lastBuildDate>Thu, 01 Aug 2024 14:08:21 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://bloggingthree.soflytech.com/wp-content/uploads/2024/04/cropped-THE-USA1-e1713184454543-1-32x32.png</url>
	<title>latestage &#8211; USA NEWS LIVE</title>
	<link>https://bloggingthree.soflytech.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Eli Lilly&#039;s weight-loss drug Zepbound lowers heart failure risk in late-stage study</title>
		<link>https://bloggingthree.soflytech.com/2024/08/eli-lillys-weight-loss-drug-zepbound-lowers-heart-failure-risk-in-late-stage-study/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Thu, 01 Aug 2024 14:08:21 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[drug]]></category>
		<category><![CDATA[Eli]]></category>
		<category><![CDATA[failure]]></category>
		<category><![CDATA[heart]]></category>
		<category><![CDATA[latestage]]></category>
		<category><![CDATA[Lilly39s]]></category>
		<category><![CDATA[lowers]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[weightloss]]></category>
		<category><![CDATA[Zepbound]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=10592</guid>

					<description><![CDATA[Eli LillyThe weight reduction drug Zepbound showed advantages in patients with common kind of heart failure and obesity, in response to Data from late-stage studies the corporate announced on Thursday. The results provide further evidence that Zepbound and other popular GLP-1 drugs offer health advantages beyond promoting weight reduction and regulating blood sugar levels, potentially [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p><span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-1">Eli Lilly<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>The weight reduction drug Zepbound showed advantages in patients with <a href="https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-successful-phase-3-study-showing-benefit" target="_blank" rel="noopener">common kind of heart failure</a> and obesity, in response to <a href="https://www.prnewswire.com/news-releases/lillys-tirzepatide-successful-in-phase-3-study-showing-benefit-in-adults-with-heart-failure-with-preserved-ejection-fraction-and-obesity-302211753.html" target="_blank" rel="noopener">Data from late-stage studies</a> the corporate announced on Thursday. </p>
<p>The results provide further evidence that Zepbound and other popular GLP-1 drugs offer health advantages beyond promoting weight reduction and regulating blood sugar levels, potentially resulting in broader coverage of those treatments by health insurers.</p>
<p>Eli Lilly announced that the corporate will present the outcomes of the Phase 3 trial to U.S. regulators and other authorities later this 12 months. </p>
<p>Eli Lilly shares rose greater than 3% in morning trading Thursday.</p>
<p>Patients taking Zepbound were 38% less prone to be hospitalized or die from heart complications and were less prone to need a dose increase.<strong> </strong>The study found that patients who received a placebo were more compliant with their heart failure medications than those that received a placebo. Zepbound also significantly improved heart failure symptoms and physical limitations, Eli Lilly said in a press release. </p>
<p>On average, the study followed greater than 700 patients with heart failure with preserved ejection fraction (HFpEF) and obesity for 2 years. Some patients also suffered from diabetes.</p>
<p>In HFpEF, the center is not any longer in a position to pump enough blood to satisfy the body&#39;s needs. Eli Lilly said the condition is related to a &#8220;high burden&#8221; of symptoms and physical limitations that affect the patient&#39;s every day life, including fatigue, shortness of breath and reduced physical performance, to call just a few. </p>
<p>About 6.7 million adults ages 20 and older within the United States suffer from heart failure, in response to the <a href="https://www.cdc.gov/heart-disease/about/heart-failure.html" target="_blank" rel="noopener">latest estimates</a> from the Centers for Disease Control and Prevention. </p>
<p>Eli Lilly estimates that HFpEF accounts for nearly half of all heart failure cases, and within the United States, nearly 60% of affected patients also suffer from obesity. </p>
</div>
<div class="group">
<div class="RelatedContent-relatedContent" id="RegularArticle-RelatedContent-1">
<div class="RelatedContent-container">
<div class="RelatedContent-nonCollapsibleContent">
<h2 class="RelatedContent-header">More health reports from CNBC</h2>
</div>
</div>
</div>
</div>
<div class="group">
<p>The safety data for Zepbound were consistent with previous studies evaluating the drug. The most typical uncomfortable side effects were gastrointestinal in nature, akin to nausea and diarrhea, and were mild to moderate in severity. </p>
<p>Eli Lilly will present the info at an upcoming medical meeting and submit them to a peer-reviewed journal. </p>
<p>The pharmaceutical giant&#39;s essential competitor within the GLP-1 market, Novo Nordisk, is already one step ahead. </p>
<p>Novo Nordisk submitted an application earlier this 12 months for the usage of its weight-loss drug Wegovy to treat patients with HFpEF. The Food and Drug Administration also gave Wegovy the green light in March since it dramatically reduces the chance of significant heart complications. </p>
<p>Meanwhile, each Novo Nordisk and Eli Lilly have tested their respective drugs on patients with chronic kidney disease and fatty liver disease, in addition to other diseases. GLP-1s work by mimicking hormones produced within the gut to suppress an individual&#39;s appetite and regulate their blood sugar.</p>
<p>But Zepbound targets each the GLP-1 and GIP hormone receptors, while Wegovy only targets GLP-1.</p>
</p>
</div>
<div class="group">
<div class="RelatedContent-relatedContent" id="RegularArticle-RelatedContent-2">
<div class="RelatedContent-container">
<div class="RelatedContent-nonCollapsibleContent">
<h2 class="RelatedContent-header">Don&#39;t miss these insights from CNBC PRO</h2>
</div>
</div>
</div>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/108001062-1719945039163-gettyimages-2126120470-ZEPBOUND_PATIENT_SHORTAGES.jpeg?v=1719945079&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
		<item>
		<title>Viking Therapeutics shares rise 16% after the pharmaceutical company moves its weight-loss injection into late-stage testing</title>
		<link>https://bloggingthree.soflytech.com/2024/07/viking-therapeutics-shares-rise-16-after-the-pharmaceutical-company-moves-its-weight-loss-injection-into-late-stage-testing/</link>
		
		<dc:creator><![CDATA[chandankumarsoft]]></dc:creator>
		<pubDate>Thu, 25 Jul 2024 13:34:34 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[company]]></category>
		<category><![CDATA[injection]]></category>
		<category><![CDATA[latestage]]></category>
		<category><![CDATA[moves]]></category>
		<category><![CDATA[Pharmaceutical]]></category>
		<category><![CDATA[rise]]></category>
		<category><![CDATA[shares]]></category>
		<category><![CDATA[testing]]></category>
		<category><![CDATA[Therapeutics]]></category>
		<category><![CDATA[Viking]]></category>
		<category><![CDATA[weightloss]]></category>
		<guid isPermaLink="false">https://bloggingthree.soflytech.com/?p=9953</guid>

					<description><![CDATA[Shares of Viking Therapeutics rose 16% in premarket trading on Thursday after the biotech company announced a day earlier plans to advance its experimental weight-loss injection into a complicated testing phase sooner than expected. This brings the San Diego-based company one step closer to entering the extremely popular GLP-1 market, which analysts say is developing [&#8230;]]]></description>
										<content:encoded><![CDATA[<p></p>
<div id="RegularArticle-ArticleBody-5" data-module="ArticleBody" data-test="articleBody-2" data-analytics="RegularArticle-articleBody-5-2"><span class="HighlightShare-hidden" style="top:0;left:0"></span></p>
<div class="group">
<p>Shares of <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-1">Viking Therapeutics<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    rose 16% in premarket trading on Thursday after the biotech company announced a day earlier <a href="https://www.prnewswire.com/news-releases/viking-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-update-302205767.html" target="_blank" rel="noopener">plans</a> to advance its experimental weight-loss injection into a complicated testing phase sooner than expected. </p>
<p>This brings the San Diego-based company one step closer to entering the extremely popular GLP-1 market, which analysts say is developing right into a <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/weight-loss-drug-forecasts-jump-150-billion-supply-grows-2024-05-28/" target="_blank" rel="noopener">150 billion dollar market</a> until the top of the last decade. </p>
<p>Viking is considered one of several small and enormous pharmaceutical corporations that need to compete on this area <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-6">Novo Nordisk<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>    And <span class="QuoteInBody-quoteNameContainer" data-test="QuoteInBody" id="RegularArticle-QuoteInBody-7">Eli Lilly<span class="QuoteInBody-inlineButton"><span class="AddToWatchlistButton-watchlistContainer" id="-WatchlistDropdown" data-analytics-id="-WatchlistDropdown"><button class="AddToWatchlistButton-watchlistButton" aria-label="Add To Watchlist" data-testid="dropdown-btn"><span class="AddToWatchlistButton-addWatchListFromTag"></span></button></span></span></span>whose demand for GLP-1 antibodies for weight reduction and diabetes has skyrocketed within the last two years. </p>
<p>Shares of Novo Nordisk and Eli Lilly fell about 2 percent in premarket trading on Thursday. </p>
<p>Viking had previously stated that the corporate expected to start one other interim study of its weekly injection, called VK2735, after the corporate reported positive results from one other phase two study in late February. </p>
<p>But after the corporate received written feedback from the U.S. Food and Drug Administration (FDA), it decided to maneuver the injection directly right into a Phase 3 trial, CEO Brian Lian said during a conference call on Wednesday. </p>
<p>Lian said the corporate is preparing to satisfy with the FDA within the fourth quarter to debate the design and timing of this Phase 3 trial, with plans to initiate the study afterward.</p>
<p>The decision will likely shorten Viking&#39;s development timeline for the injection by a 12 months, BTIG analyst Justin Zelin said in a note Wednesday. Currently, analysts expect the drug to hit the market in 2029, Zelin said. </p>
<p>During the decision, Lian added that Viking plans to check VK2735 as a monthly injection in a future study, which could make the treatment a more convenient option than Eli Lilly&#39;s Zepbound and Novo Nordisk&#39;s Wegovy, each of that are taken once every week.</p>
<p>Viking Therapeutics&#39; drug promotes weight reduction by targeting GLP-1 and one other hormone called GIP, the identical hormones targeted by Eli Lilly&#39;s Zepbound and its diabetes counterpart Mounjaro.</p>
<p>Patients who received the Viking injection weekly in a Phase 2 study lost as much as 14.7 percent of their body weight after 13 weeks, or 13.1 percent in comparison with placebo. </p>
<p>Viking can be developing an oral version of VK2735. This pill resulted in a weight reduction of three.3% in comparison with a placebo in an early study. </p>
</div>
</div>
<p><em>image credit : www.cnbc.com</em></p>
]]></content:encoded>
					
		
		
		<media:content url="https://image.cnbcfm.com/api/v1/image/107378853-1709040141961-gettyimages-1665778558-img_5416-1.jpeg?v=1721911495&#038;w=1920&#038;h=1080" medium="image"></media:content>
	</item>
	</channel>
</rss>
